Hideko Ohama

Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis

Margherita Rimini, Lorenza Rimassa, Kazuomi Ueshima et al. · ESMO Open · 2022 · 130 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +14

Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population

Andrea Casadei‐Gardini, Margherita Rimini, Toshifumi Tada et al. · European Journal of Cancer · 2022 · 129 citations · Full text

Medicine, Oncology, Pharmacology +15

Neutrophil‐to‐lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib

Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka et al. · Liver International · 2020 · 97 citations · Full text

Medicine, Oncology, Pharmacology +11

Lipopolysaccharides accelerate hepatic steatosis in the development of nonalcoholic fatty liver disease in Zucker rats

Shinya Fukunishi, Tetsuya Sujishi, Atsushi Takeshita et al. · Journal of Clinical Biochemistry and Nutrition · 2013 · 88 citations · Full text

Medicine, Biochemistry, Pathobiology +12

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience

Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada et al. · Cancer Reports · 2021 · 80 citations · Full text

Medicine, Oncology, Pharmacotherapy +17